The Sri Lanka Chamber of the Pharmaceutical Industry (SLCPI) has issued a pressing appeal for decisive measures to avert a potential crisis in the availability of medicines in Sri Lanka. The organization has raised concerns that escalating challenges within the pharmaceutical supply chain could hinder the nation’s ability to provide continuous access to vital and life-saving medications.
The SLCPI warned that without prompt and effective interventions, the country may experience heightened shortages in both private and public healthcare sectors, creating significant challenges for patients, hospitals, pharmacies, and the broader healthcare system. This issue has transcended the pharmaceutical industry, now representing a national concern with serious implications for public health, the continuity of care, and the country’s capacity to meet everyday and emergency medical needs.
The Chamber highlighted several contributing factors to this situation, including rising global supply chain costs, pressures related to exchange rates, increases in freight and fuel costs, delays in import licensing, and surging compliance and clearance fees. These elements are making it increasingly challenging to maintain a steady influx of medicines into the nation. Given Sri Lanka’s heavy reliance on imported pharmaceuticals and raw materials, the country is particularly susceptible to fluctuations in the global market and domestic logistical delays.
The SLCPI emphasized that medicines are not mere commodities; they are critical for daily treatments, emergency care, chronic disease management, and life-saving procedures. The reliable supply of these medicines depends on a meticulously regulated and managed supply chain. Each phase of this process, from sourcing and quality checks to temperature-controlled storage, secure transport, compliant handling, and timely import clearances, is essential to ensure that safe and effective medications reach those in need.
Recently, the integrity of this system has faced mounting pressure. Fuel costs have surged by approximately 38%, with further increases anticipated. Freight rates have escalated by over 40%, and global prices for active pharmaceutical ingredients, solvents, and packaging materials have soared, in some instances by as much as 70%. Concurrently, the depreciation of the Sri Lankan Rupee against the US Dollar has significantly raised import expenses, intensifying the strain on the supply chain.
The Chamber pointed out that these challenges are exacerbated by delays in the import license renewal and pricing review processes. When the timely movement of medicines through the system is disrupted, suppliers encounter increasing difficulties in placing orders, clearing shipments, and maintaining consistent supply. In a country like Sri Lanka, where order sizes are relatively modest and continuity hinges on timely approvals and predictable systems, even minor delays can swiftly escalate into stock shortages and widespread disruptions.
“This issue has evolved beyond industry-specific concerns; it is now a matter of national preparedness and ensuring continuity of care. Without immediate action, the country risks entering a state where medicine shortages become inevitable and recovery from such a situation grows increasingly difficult,” stated the Chamber.
The SLCPI warned that failing to act will have repercussions that extend well beyond the pharmaceutical sector. Patients may experience delays in receiving treatment or struggle to access essential medications. Hospitals and pharmacies could face mounting pressure as supplies become unreliable. Healthcare providers may be compelled to make challenging decisions due to limited availability, adversely affecting families nationwide who depend on consistent access to necessary medications.
Furthermore, the SLCPI cautioned that prolonged strain on the regulated pharmaceutical supply chain could pose broader risks to the market and public safety. As legitimate supply becomes harder to maintain, shortages and restricted access may open doors for unauthorized and illegal channels to infiltrate the market, heightening the risk of substandard or counterfeit medicines reaching consumers, thereby jeopardizing patient safety and eroding trust in the healthcare system.
The Chamber underscored the importance of preventing a scenario where the availability of safe, regulated medicines is compromised. The immediate focus should be on reinforcing the systems that facilitate the flow of medicines, safeguarding the integrity of the supply chain, and ensuring uninterrupted access to necessary treatments for patients across the country.
In light of these concerns, the SLCPI has urged government authorities to implement urgent and practical measures to stabilize the medicine supply chain. This includes addressing delays in import license processing, enhancing coordination between import license renewals and pricing reviews, and acknowledging the significant rise in operational, freight, exchange, and input-related costs that threaten the sustainability of supply.
“Sri Lanka must take action now to avert a medicine shortage crisis. The consequences of inaction will manifest as delayed treatments, reduced availability, and increased pressure on patients, pharmacies, hospitals, and the overall healthcare system,” the Chamber warned.
The SLCPI reaffirmed its commitment to a singular focus: ensuring that Sri Lankans maintain uninterrupted access to safe, effective, and properly regulated medicines. The Chamber expressed its dedication to collaborating constructively with regulators and policymakers to facilitate solutions that uphold the continuity of supply and public confidence.
As pressures mount, the SLCPI has called upon all relevant stakeholders to treat this situation with urgency and to engage in coordinated efforts before the current strain on the supply chain escalates into a national medicine shortage.
